UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells.
Yan WuDan JinXiaohong WangJing DuWeihua DiJiajia AnCuijie ShaoJiwei GuoPublished in: Journal of oncology (2019)
UBE2C may be a novel therapy target for NSCLC for sensitizing cells to the chemotherapeutic agent DDP.